Eli Lilly released data showing that retatrutide, an experimental injectable drug, produced dramatic weight loss results in clinical trials. Participants lost an average of 28 percent of their body weight over 80 weeks of treatment.
This result far exceeds the weight loss achieved by currently available medications. Semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) produce weight losses in the 15 to 22 percent range. Retatrutide works through a different mechanism, targeting three hormone receptors in the body rather than two, which may explain the larger effect.
The drug belongs to a class called GLP-1 receptor agonists, medications that mimic hormones controlling hunger and blood sugar. Retatrutide additionally targets GIP and glucagon receptors, hormones that regulate metabolism and appetite independently.
Eli Lilly has not yet published full clinical trial data in a peer-reviewed journal, so independent verification remains pending. The company has not disclosed details about side effects, safety concerns, or how participants tolerated the medication over the 80-week period. Weight loss medications in this class commonly cause nausea, vomiting, and gastrointestinal issues, particularly when doses increase.
The FDA has not yet approved retatrutide for weight loss. The company is pursuing regulatory review, but the timeline for potential approval remains unclear. If approved, retatrutide could reshape the obesity treatment landscape, particularly for people who have not achieved adequate results with existing medications.
The 28 percent weight loss figure represents a meaningful threshold. Most obesity specialists consider losses above 25 percent clinically significant, offering substantial improvements in diabetes risk, blood pressure, and joint stress. Whether this benefit translates to real-world outcomes depends on how well people tolerate the drug long